Pharmacology Drug Metabolism and Disposition
Two Mechanisms Explain Vismodegib's Dose-Independent Exposure in a PBPK Model
- Vismodegib shows less accumulation than linear PK predicts, a faster approach to steady state and similar steady-state levels across a wide dose range.
- New in vitro binding work to alpha-1-acid glycoprotein and albumin was built into a PBPK model that already included nonsink permeation.
- Simulations suggest saturable AAG binding raises total clearance as concentrations rise, while nonsink permeation limits absorption; both contribute.
This is a clean example of nonlinearity that isn't enzyme saturation: saturable binding to a minor, variable plasma protein plus a solubility-limited absorption step. Since AAG rises in inflammation and cancer, I'd ask how the model behaves with patient-level AAG variability, and whether unbound exposure, the part that matters for efficacy, is flat or still rising with dose.
Paper: Drug Metabolism and Disposition ↗ Investigation of the Nonlinear Pharmacokinetics of Vismodegib in Humans: Using PBPK Modeling to Examine Contributions of Saturable Plasma Protein Binding and Nonsink Permeation